FTSE MIB
35.042,31 +226,40 (+0,65%) Dow Jones
39.489,77 +58,26 (+0,15%) Nasdaq
16.456,73 +68,49 (+0,42%) Nikkei 225
38.356,06 +176,60 (+0,46%) Petrolio
78,54 -0,58 (-0,73%) Bitcoin EUR
57.378,74 -730,42 (-1,26%)
CLLS May 2024 7.500 put
| Chiusura precedente | 5,0000 |
| Aperto | 5,0000 |
| Denaro | 3,4000 |
| Lettera | 6,1000 |
| Prezzo d'esercizio | 7,50 |
| Scadenza | 2024-05-17 |
| Min-Max giorno | 5,0000 - 5,0000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | N/D |
GlobeNewswireCellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)
NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy – Methods & Clinical Development, demonstrating the efficacy of its TALEN-mediated gene correction of mutated PIK3CD gene in APDS1 T-cells. The research work described in this articl
- GlobeNewswire
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority)PARIS, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights09/30/202355,583,76861,519,946 About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherap
- GlobeNewswire
Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical data on MUC1-CAR T-cells to overcome key challenges of targeting solid tumors, will be presented at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023), that will take place on November 1-5, 2023 at San
